International Journal of Gynecological Cancer

Papers
(The H4-Index of International Journal of Gynecological Cancer is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Inguinofemoral lymphadenectomy technique in 10 steps442
The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization207
The Cukurova score in the prediction of primary cytoreduction in ovarian cancer154
Successful cervical cancer treatment during a monochorionic diamniotic twin pregnancy in a patient with history of preterm delivery105
Well-differentiated papillary mesothelial tumor of the peritoneum92
Complementary use of indocyanine green and technetium to enhance sentinel lymphadenectomy in vulvar cancer86
A population-based study of outcomes in adjuvant radiotherapy for stage II endometrial carcinoma71
Surgical technique and surgeon volume: the pursuit of data-driven outcomes66
Best original research presented at the 25th European Congress on Gynaecological Oncology: best of ESGO 202464
O021/#374 Breast cancer patients are at increased risk of devoleping uterine serous cancer: implication for conseling – a seer analysis63
Authors’ response to: “Methodological concerns regarding AGO score validation in low-grade ovarian cancers”63
22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report60
CERVICAL MELANOMA WITH CEREBRAL DISSEMINATION: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE IN GYNECOLOGIC ONCOLOGY59
HYPOFRACTIONATED RADIATION THERAPY WITH ADAPTIVE PLANNING FOR THE TREATMENT OF ENDOMETRIAL AND CERVICAL CANCER (HERA TRIAL)59
HIDDEN IN PLAIN SIGHT: DESMOPLASTIC SMALL ROUND CELL TUMOUR (DSRCT) PRESENTING AS A GYNAECOLOGICAL MALIGNANCY58
COST-UTILITY ANALYSIS OF A MOLECULAR-INTEGRATED-PROFILE FOR WOMEN WITH (HIGH)INTERMEDIATE RISK ENDOMETRIAL CANCER - PORTEC-4A AN INTERNATIONAL, MULTICENTRE, RANDOMISED, PHASE 3 TRIAL52
INTRA-OPERATIVE COMPLICATIONS OF GYNECOLOGIC ONCOLOGY SURGERIES IN A TEACHING HOSPITAL IN SUB-SAHARAN AFRICA: EXPERIENCE FROM ADDIS ABABA, ETHIOPIA51
LOWER LIMB LYMPHEDEMA AFTER TREATMENT OF CERVICAL CARCINOMA AND ITS IMPACT ON QUALITY OF LIFE49
COLPOSCOPIC-HISTOLOGIC DIAGNOSTIC AGREEMENT IN CERVICAL INTRAEPITHELIAL NEOPLASIA 2+: A FIVE-YEAR REVIEW OF COLPOSCOPIC SERVICES AT THE NATIONAL HOSPITAL ABUJA, NIGERIA COLPOSCOPIC-HISTOLOGIC DIAGNOST48
SIGNIFICANCE & CLINICAL UTILITY OF 2-DEOXY-2-[18F] FLUORO-D-GLUCOSE-POSITRON EMISSION TOMOGRAPHY HIBRID IMAGING IN THE DIAGNOSIS & RESPONSE EVALUATION IN CERVIX CANCER.46
THE LANDSCAPE OF VULVAR CANCER SURVIVAL AND TREATMENT CHARACTERISTICS IN BOTSWANA46
A POTENTIAL BLIND SPOT FOR ANTIBODY–DRUG CONJUGATES TARGETING FOLATE RECEPTOR-146
PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-82645
2022-RA-1495-ESGO Differential metabolism of estrogens in model cell lines and tissues of HGSOC subtypes42
2022-RA-1127-ESGO The efficacy of MEK inhibitors in the treatment of low-grade serous ovarian cancers: a systematic review41
2022-RA-1001-ESGO Analysis of postoperative wound infections in malignancies of the female internal tract40
2022-RA-981-ESGO Can misdiagnosis be avoided in case of intestinal-type carcinoma of the vagina?A literature comprehensive review39
2022-RA-630-ESGO Overexpression of PDEA1 is a predictive biomarker for platinum resistance and poor prognosis in epithelial ovarian cancer by regulating cell cycle39
2022-RA-1690-ESGO Rare uterine cervical adenocarcinomas in salah azaiez institute: clinicopathological features38
2022-RA-1318-ESGO Immunohistochemical profiling of macrophage subtypes in the microenvironment of ovarian tumours in young women37
2022-RA-1187-ESGO Management and outcomes in high risk GTN – a regional cancer center experience35
2022-RA-1387-ESGO Patients with minimal residual disease at upfront debulking surgery have similar survival outcome than patients with complete cytorreduction after neoadjuvant chemotherapy35
2022-RA-991-ESGO Assessment of high-risk human papillomavirus infections and cervical dysplasia in human immunodeficiency virus-positive pregnant women in germany: a prospective cross-sectional two-ce35
2022-RA-1194-ESGO Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study35
2022-RA-684-ESGO Factors affecting survival outcomes of patients with clear cell endometrial carcinoma35
0.36399912834167